What is Hematopoietic Progenitor Cell Cord Blood
Hematopoietic progenitor cell cord blood infusion promotes progenitor/stem cell migration to the bone marrow where cells divide, mature, and are released into the bloodstream.
These mature cells can then partially or fully restore blood counts and function in patients with malignant hematological disease.
In a retrospective analysis of 1086 pediatric or adult patients (median age, 6.6 years; range, 0.05 to 70 years) with hematologic malignancies who received HPC, cord blood (Allocord) as part of a cord blood transplant (CBT), 88% of patients achieved neutrophil engraftment by day 42 (median time to engraftment, 21 days).
By day 100, platelet engraftment (platelet count of >= 50,000 cells/mcL) occurred in 79% of patients; the median time to engraftment was 56 days.
Additionally, the efficacy and safety of HPC, cord blood was evaluated in adult (n = 34) and pediatric (n = 191) patients with hematologic malignancies who received an unrelated CBT in a multicenter, phase II trial (the COBLT trial).
In May 2013, the FDA approved HPC, cord blood (Allocord) for use in unrelated donor hematopoietic stem cell transplant in combination with an appropriate stem cell preparative regimen in patients with hematopoietic system disorders that are inherited, acquired, or result from myeloablative treatment.
- stem cell transplant
For use in unrelated donor hematopoietic stem cell transplant in combination with an appropriate stem cell preparative regimen in patients with hematopoietic system disorders that are inherited, acquired, or result from myeloablative treatment
NOTE: Matching for at least 4 of 6 HLA-A antigens, HLA-B antigens, and HLA-DRB1 alleles is recommended.
- CBC with differential
- serum bilirubin
- serum creatinine/BUN
- albumin hypersensitivity
- cardiac arrest
- cardiac arrhythmias
- infusion-related reactions
- plasma protein hypersensitivity
- post-transplant lymphoproliferative disorder (PTLD)
- renal failure
- renal impairment
- viral infection
No information is available regarding drug interactions associated with Hematopoietic Progenitor Cell Cord Blood